DK1025088T3 - Imidazolderivater og deres anvendelse som farnesylproteintransferaseinhibitorer - Google Patents
Imidazolderivater og deres anvendelse som farnesylproteintransferaseinhibitorerInfo
- Publication number
- DK1025088T3 DK1025088T3 DK98947694T DK98947694T DK1025088T3 DK 1025088 T3 DK1025088 T3 DK 1025088T3 DK 98947694 T DK98947694 T DK 98947694T DK 98947694 T DK98947694 T DK 98947694T DK 1025088 T3 DK1025088 T3 DK 1025088T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- phenyl
- protein transferase
- imidazole derivatives
- transferase inhibitors
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000686 lactone group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97402502 | 1997-10-22 | ||
| EP97402505 | 1997-10-22 | ||
| PCT/GB1998/003117 WO1999020611A1 (en) | 1997-10-22 | 1998-10-19 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1025088T3 true DK1025088T3 (da) | 2001-11-12 |
Family
ID=26147905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98947694T DK1025088T3 (da) | 1997-10-22 | 1998-10-19 | Imidazolderivater og deres anvendelse som farnesylproteintransferaseinhibitorer |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6342765B1 (da) |
| EP (1) | EP1025088B1 (da) |
| JP (1) | JP2001524455A (da) |
| AT (1) | ATE205195T1 (da) |
| AU (1) | AU9453098A (da) |
| DE (1) | DE69801590T2 (da) |
| DK (1) | DK1025088T3 (da) |
| ES (1) | ES2163295T3 (da) |
| PT (1) | PT1025088E (da) |
| WO (1) | WO1999020611A1 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284755B1 (en) | 1998-12-08 | 2001-09-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2000034239A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU1872900A (en) | 1998-12-23 | 2000-07-31 | Astrazeneca Ab | Chemical compounds |
| WO2001014314A1 (en) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives having aromatic substituents and processes for the preparation thereof |
| GB9930317D0 (en) | 1999-12-22 | 2000-02-09 | Zeneca Ltd | Novel compounds |
| US6271418B1 (en) | 2000-02-22 | 2001-08-07 | Nippon Kayaku Co., Ltd. | Process for preparing (hetero) aromatic substituted benzene derivatives |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| EP1539234A4 (en) * | 2002-09-05 | 2006-02-15 | Medimmune Inc | METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| EP2316487B1 (en) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン，エルエルシー | 抗体のフレームワーク・シャッフル |
| JP2008546805A (ja) | 2005-06-23 | 2008-12-25 | メディミューン，エルエルシー | 最適な凝集および断片化プロフィールを有する抗体製剤 |
| JP4651714B2 (ja) | 2005-07-09 | 2011-03-16 | アストラゼネカ アクチボラグ | 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体 |
| NZ596091A (en) | 2006-08-28 | 2012-07-27 | Jolla Inst Allergy Immunolog | Antagonistic human light-specific human monoclonal antibodies |
| WO2008121615A2 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Inc. | Antibody formulation |
| BRPI0818810A2 (pt) | 2007-10-31 | 2014-10-29 | Medimmune Llc | Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável. |
| US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| SG11201502757QA (en) | 2012-10-09 | 2015-05-28 | Igenica Biotherapeutics Inc | Anti-c16orf54 antibodies and methods of use thereof |
| EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| KR20160054501A (ko) | 2013-08-26 | 2016-05-16 | 맵백스 테라퓨틱스, 인코포레이티드 | 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| HUE055189T2 (hu) | 2014-06-04 | 2021-11-29 | Biontech Res And Development Inc | Humán monoklonális antitestek a GD2 ganglioziddal ellen |
| DK3333191T3 (da) | 2014-12-11 | 2020-10-26 | Pf Medicament | Anti-C10ORF54-antistoffer og anvendelser deraf |
| RU2725221C2 (ru) | 2015-03-03 | 2020-06-30 | Кимаб Лимитед | Антитела, их применение и способы применения |
| MX2018006613A (es) | 2015-12-02 | 2019-01-30 | Stcube & Co Inc | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. |
| KR102815803B1 (ko) | 2015-12-02 | 2025-06-05 | 주식회사 에스티사이언스 | 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| JP7768666B2 (ja) | 2017-05-31 | 2025-11-12 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法 |
| WO2018226671A1 (en) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
| JP7256796B2 (ja) | 2017-10-13 | 2023-04-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体 |
| US20230243836A1 (en) | 2018-07-20 | 2023-08-03 | Pierre Fabre Medicament | Receptor for vista |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5944308B2 (ja) | 1976-03-23 | 1984-10-29 | 武田薬品工業株式会社 | ペプタイド |
| US4221803A (en) * | 1979-05-09 | 1980-09-09 | Recordati, S.A. | Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections |
| FI803127A7 (fi) | 1979-10-03 | 1981-04-04 | Glaxo Group Ltd | Heterosyklisiä yhdisteitä. |
| US4518607A (en) * | 1983-07-18 | 1985-05-21 | Syntex (U.S.A.) Inc. | Male oral contraceptive N-alkylimidazole derivatives, compositions, and method of use therefor |
| US5298655A (en) | 1991-09-27 | 1994-03-29 | Merck & Co., Inc. | Farnesyl pyrophosphate analogs |
| US5238922A (en) | 1991-09-30 | 1993-08-24 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5340828A (en) | 1991-09-30 | 1994-08-23 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5352705A (en) | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5326773A (en) | 1992-10-29 | 1994-07-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU2122795A (en) | 1994-03-15 | 1995-10-03 | Eisai Co. Ltd. | Isoprenyl transferase inhibitors |
| CA2155448A1 (en) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
| US5478934A (en) | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
| JPH11503419A (ja) * | 1995-03-29 | 1999-03-26 | メルク エンド カンパニー インコーポレーテッド | ファルネシル−タンパク質トランスフェラーゼ阻害剤 |
| US5534537A (en) * | 1995-03-29 | 1996-07-09 | Merck & Co., Inc. | Prodrugs of inhibitors of farnesyl-protein transferase |
| US5710171A (en) | 1995-05-24 | 1998-01-20 | Merck & Co., Inc. | Bisphenyl inhibitors of farnesyl-protein transferase |
| GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
| ATE236632T1 (de) | 1995-11-06 | 2003-04-15 | Univ Pittsburgh | Inhibitoren der protein-isoprenyl-transferase |
| WO1998032741A1 (en) | 1997-01-29 | 1998-07-30 | Zeneca Limited | Inhibitors of farnesyl protein transferase |
-
1998
- 1998-10-19 DK DK98947694T patent/DK1025088T3/da active
- 1998-10-19 JP JP2000516953A patent/JP2001524455A/ja not_active Withdrawn
- 1998-10-19 WO PCT/GB1998/003117 patent/WO1999020611A1/en not_active Ceased
- 1998-10-19 AT AT98947694T patent/ATE205195T1/de not_active IP Right Cessation
- 1998-10-19 AU AU94530/98A patent/AU9453098A/en not_active Abandoned
- 1998-10-19 DE DE69801590T patent/DE69801590T2/de not_active Expired - Fee Related
- 1998-10-19 PT PT80103281T patent/PT1025088E/pt unknown
- 1998-10-19 US US09/509,210 patent/US6342765B1/en not_active Expired - Fee Related
- 1998-10-19 ES ES98947694T patent/ES2163295T3/es not_active Expired - Lifetime
- 1998-10-19 EP EP98947694A patent/EP1025088B1/en not_active Expired - Lifetime
-
2001
- 2001-09-20 US US09/955,994 patent/US20020052376A1/en not_active Abandoned
- 2001-09-20 US US09/956,005 patent/US20020058665A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6342765B1 (en) | 2002-01-29 |
| JP2001524455A (ja) | 2001-12-04 |
| US20020052376A1 (en) | 2002-05-02 |
| AU9453098A (en) | 1999-05-10 |
| DE69801590T2 (de) | 2002-07-11 |
| WO1999020611A1 (en) | 1999-04-29 |
| ATE205195T1 (de) | 2001-09-15 |
| DE69801590D1 (de) | 2001-10-11 |
| US20020058665A1 (en) | 2002-05-16 |
| EP1025088B1 (en) | 2001-09-05 |
| PT1025088E (pt) | 2002-01-30 |
| EP1025088A1 (en) | 2000-08-09 |
| ES2163295T3 (es) | 2002-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1025088T3 (da) | Imidazolderivater og deres anvendelse som farnesylproteintransferaseinhibitorer | |
| BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
| BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
| BR0014116A (pt) | Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BRPI0616799B8 (pt) | derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
| BR0014133A (pt) | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BRPI9608082B8 (pt) | derivado de quinazolina, sal de cloridreto do mesmo, e, composição farmacêutica | |
| BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
| BR9812046A (pt) | Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto | |
| NO20023218L (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| ES2193362T3 (es) | Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos. | |
| BR9809062A (pt) | Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos | |
| BR0210874A (pt) | Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso | |
| BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| DK1165544T3 (da) | Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase | |
| ATE269865T1 (de) | Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren | |
| BR0214695A (pt) | Derivados de pirazol com anel fundido | |
| AR021826A1 (es) | COMPUESTOS DE 2- FENILPIRAN-4-ONA, PROCESOS PARA PREPARARLOS, USO DE UN COMPUESTO INTERMEDIARIO EN DICHOS, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y USO DE DICHOS COMPUESTOS Y DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO | |
| BG106847A (bg) | Заместени пиперазинови производни като инхибиторина микрозомалния триглицеридпренасящ протеин (mtp) | |
| BR0209332A (pt) | Derivados de ftalazina com atividade inibidora da angiogênese |